Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 69 clinical trials
A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer

This study is being done to see if tucatinib with ado-trastuzumab emtansine (T-DM1) works better than T-DM1 alone to help patients who have a specific type of breast cancer called HER2 positive breast carcinoma. The breast cancer in this study is either metastatic (spread into other parts of the body) …

breast cancer
brain metastases
taxane
metastasis
tucatinib
  • 24 views
  • 10 Jun, 2021
  • 202 locations
Pre Operative Trastuzumab in Operable Breast Cancer

Background Information and Rationale: Trastuzumab is a humanized monoclonal antibody that acts extracellularly on the erbB-2 receptor.Trastuzumab is a recombinant humanized IgG1 monoclonal antibody against the human epidermal growth factor receptor 2 (HER2/erbB-2),which has shown in both in vitro assays and in animals, to inhibit the proliferation of human tumour …

hormone therapy
platelet count
adjuvant chemotherapy
tumor cells
herceptin
  • 71 views
  • 26 Jan, 2021
  • 1 location
To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH)

This is a phase II open-label, multicentre, randomized trial. The study assesses the treatment of postmenopausal patients with hormone receptor positive/HER2 positive early breast cancer with neoadjuvant palbociclib in combination with hormonal therapy and HER2 blockade, versus the treatment with paclitaxel in combination with HER2 blockade.

hormone therapy
primary tumor
tamoxifen
metastasis
her2/neu-positive breast cancer
  • 17 views
  • 11 May, 2021
  • 63 locations
A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms

The primary goal of this Phase 1 study is to characterize the safety and tolerability of MGD013 and establish the maximum tolerated dose (MTD) of MGD013. Pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD), and the anti-tumor activity of MGD013 will also be assessed.

cancer
erbb2
solid tumour
measurable disease
HER2
  • 534 views
  • 17 Feb, 2021
  • 70 locations
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer the CompassHER2 RD Trial

This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted …

  • 0 views
  • 14 Jun, 2021
  • 740 locations
Tucatinib Trastuzumab and Capecitabine for the Treatment of HER2+ LMD

positive breast cancer.

hormone therapy
metastasis
international normalized ratio
carcinoma
thromboplastin
  • 0 views
  • 21 Apr, 2021
  • 7 locations
Monitoring HER2+ Breast Cancer Neoadjuvant Treatment With Advanced PET/MRI

The purpose of the study is to see if using an investigational drug called [18F]FMISO with PET/MRI imaging can help monitor and predict the effect of trastuzumab (Herceptin) on chemotherapy in patients diagnosed with advanced HER2 positive breast cancer. This study is for imaging purposes only and is not a …

breast cancer
primary tumor
herceptin
cancer
measurable disease
  • 0 views
  • 26 Jan, 2021
  • 1 location
Adapted Physical Activity for Breast Cancer HER2 Positive Patient

The purpose of this study is to assess the feasibility of a home-based adapted physical activity during neoadjuvant chemotherapy for HER2+ breast cancer.

breast cancer
growth factor
cancer
epidermal growth factor
her-2
  • 125 views
  • 30 Apr, 2021
  • 1 location
Trastuzumab Combined With Pyrrolidine and Chemotherapy for Locally HER2 Positive Breast Cancer

This study is a one-arm, open, phase II clinical study, and the study subjects are locally advanced and inflammatoryPatients with sexual or early HER2-positive breast cancer entered the trial period after signing informed consentTo evaluate trastuzumab combined with pyrrolitinib and chemotherapy regimen (TCbH+Py) for HER2 positive breastPathologic complete response rate …

breast cancer
platelet count
bisphosphonate
ejection fraction
HER2
  • 0 views
  • 25 Jan, 2021
  • 1 location
Trial of ZN-A-1041 Enteric Capsules in Patients With HER2-Positive Advanced Solid Tumors

This will be a phase 1, multicenter, open-label trial to evaluate the safety, tolerability, PK and efficacy of ZN-A-1041 as a monotherapy or in combination with Capecitabine in patients with HER2-positive advanced solid tumors with or without brain metastases. The study will consist of three phases: phase 1a (dose escalation …

breast cancer
immunohistochemistry
brain metastases
capecitabine
metastasis
  • 0 views
  • 26 Jan, 2021
  • 1 location